Where Denali Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Denali Therapeutics (NASDAQ:DNLI) has received positive analyst ratings in the last quarter, with 2 bullish and 4 somewhat bullish ratings. The average price target for the stock is $79.83, a significant increase from the previous average of $53.50, indicating a potential upside from the current price of $24.02.
August 10, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Denali Therapeutics has received positive analyst ratings, with an average price target of $79.83, indicating a potential upside from the current price of $24.02.
The positive analyst ratings and the significant increase in the average price target for Denali Therapeutics indicate a bullish sentiment for the stock. This could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100